Pre-emptive virology screening in the pediatric hematopoietic stem cell transplant population: A cost effectiveness analysis
Open Access
- 1 September 2013
- journal article
- Published by Medknow in Hematology/Oncology and Stem Cell Therapy
- Vol. 6 (3-4) , 81-88
Abstract
BACKGROUND AND OBJECTIVES: Pediatric patients undergoing hematopoietic stem cell transplant (HSCT) are at a uniquely high risk of cytomegalovirus (CMV) and Epstein–Barr virus (EBV) infections. The pre-emptive treatment model whereby asymptomatic post-transplant patients are routinely screened with treatment initiated if found viremic has recently been shown to be superior in terms of patient mortality when compared to deferring laboratory assessment and treatment until symptoms emerge. This study analyzes the cost-effectiveness of the pre-emptive therapy model in patient care dollars per quality-adjusted life years (QALY). PATIENTS AND METHODS: Utilization and outcome data were compiled as a retrospective cohort study of 96 pediatric patients receiving HSCT at University of California Los Angeles Pediatric Hematology/Oncology Department between the years 2006 and 2010. Two-decision tree models were constructed for each the preemptive model and the deferred model wherein costs and probability assumptions were based on either previously published literature or calculated from this study cohort. RESULTS: The pre-emptive model resulted in a five-year survival of 71%, during which time 4% of patients were found to be EBV viremic, while 33% were found to be CMV viremic. The average actual cost of EBV/CMV virology screening per patient in the cohort following the pre-emptive model was $9699 while the expected cost following the deferred model was $19,284. This results in an incremental cost effectiveness ratio illustrating pre-emptive model cost-savings of $2367/QALY. CONCLUSION: These results support the financial viability and prudence of scheduled screening for subclinical viremia for achieving optimal outcomes in a cost-effective manner in the pediatric HSCT population.Keywords
This publication has 17 references indexed in Scilit:
- Post‐transplant Burkitt lymphoma is a more aggressive and distinct form of post‐transplant lymphoproliferative disorderCancer, 2011
- Prospective, Comprehensive, and Effective Viral Monitoring in Children Undergoing Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2010
- Myeloma, Hodgkin Disease, and Lymphoid Leukemia after Renal Transplantation: Characteristics, Risk Factors and PrognosisTransplantation, 2006
- Management of cytomegalovirus infection by weekly surveillance after renal transplant: analysis of cost, rejection and renal functionNephrology Dialysis Transplantation, 2003
- Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell–depleted SCTBlood, 2001
- Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency VirusClinical Infectious Diseases, 2001
- Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant RecipientsBlood, 1998
- Biology and adoptive cell therapy of Epstein‐Barr virus‐associated lymphoproliferative disorders in recipients of marrow allograftsImmunological Reviews, 1997
- Prevention and treatment of CMV infection after allogeneic bone marrow transplantAnnals of Hematology, 1992
- Cytomegalovirus as a possible cause of a disease resembling infectious mononucleosis.BMJ, 1965